Fish Principal Gwilym Attwell Authors Article for Life Science Leader, "Intellectual Property Do's and Don'ts for Early-Stage Life Sciences Companies"


Early-stage life sciences companies typically focus their time and resources on developing their core products, positioning them for commercial success, and, if applicable, obtaining Food and Drug Administration (FDA) approval. Intellectual property (IP) protection is often further down their list of priorities. This is a mistake. The strength of a company's IP assets is a critical factor in determining its value; failure to protect those assets can seriously diminish a company's prospects for long-term success. Savvy companies focus on IP early and integrate their IP strategies seamlessly into their overall business strategy.

Read the full article on Life Science Leader.

Read the full Life Sciences Entrepreneur Sourcebook.